Journal
WORLD JOURNAL OF CLINICAL CASES
Volume 4, Issue 3, Pages 71-75Publisher
BAISHIDENG PUBLISHING GROUP INC
DOI: 10.12998/wjcc.v4.i3.71
Keywords
Hepatitis B virus; Hepatitis B surface antigen; Escape mutant; Hepatitis B immunoglobulin; Vaccination
Categories
Funding
- Roche Pharmaceuticals
- Bristol-Myers Squibb
- Gilead Sciences
Ask authors/readers for more resources
Approximately 240 million people are chronically infected with hepatitis B. The implementation of rigorous vaccination programs has led to an overall decrease in the prevalence of this disease worldwide but this may also have led to emergence of viral mutations that can escape the protection of hepatitis B surface antibody. As this phenomenon is increasingly recognized, concern for transmission to vaccinated individuals has also been raised. Herein, we describe two cases where the suspected presence of a hepatitis B surface antigen escape mutation impacted the decision to initiate early antiviral therapy, as well as provide a brief review of these mutations. Our findings described here suggest that a lower threshold for initiating therapy in these individuals should be considered in order to reduce the risk of transmission, as vaccination does not provide protection.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available